Zhiping Li

CN 
CN 

Overview

Zhiping Li practices practicing medicine in China.

Their clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Vaginal Cancer, Dendritic Cell Tumor, and Gastrectomy.

They are actively involved in clinical research, co-authoring 54 peer reviewed articles and participating in 2 clinical trials.

Locations

China
Other Locations
No. 37 Guoxue Lane, Wuhou District, Chengdu, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Other, Drug
Study Drug: Surufatinib
Study Phase: Phase 3
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Other, Drug
Study Drug: Surufatinib
Study Phase: Phase 3
View 1 Less Clinical Trial

54 Total Publications

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.
Journal: JAMA network open
Published: June 15, 2026

Frequently Asked Questions about Zhiping Li

Is Zhiping Li a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Zhiping Li is classified as an Experienced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhiping Li participate in research or clinical trials?

Yes. Zhiping Li has published 54 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Zhiping Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile